Heat Biologics, Inc. (NASDAQ: HTBX) Starts Presentation at 29th Annual ROTH Conference
Heat Biologics (NASDAQ: HTBX) is a biopharmaceutical company focused on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy. For more information, visit the company’s website at www.heatbio.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication…







